Key Takeaways
- • Portal Innovations' venture team released "Biotech's Next Frontier: Emerging Hubs Built for Efficiency and Outsized Returns," a ten-year analysis of more than 11,000 life sciences companies and nearly 30,000 financing deals from 2015 through 2025.
- • Companies in emerging U.S. biotech ecosystems generated higher median returns on invested capital at exit than companies in established hubs in California and Massachusetts, according to the report.
- • Startups outside traditional hubs reached their first clinical trial milestones faster on average while requiring less private capital, and experienced less founder dilution.
- • Capital raised by emerging-ecosystem companies rose 23.3% between the 2018–2021 and 2022–2025 periods, while established hubs saw a 14.7% decline.
- • Companies outside traditional hubs accounted for nearly 70% of startups receiving SBIR/STTR grants analyzed, underscoring the role of non-dilutive funding.
Summary
Portal Innovations, a Chicago-headquartered venture development platform, has released a new analysis examining a decade of financing, clinical development, and exit data across the U.S. biotechnology industry, according to a Business Wire release. The report draws on data covering more than 11,000 life sciences companies and nearly 30,000 financing deals from 2015 through 2025, and compares established biotech hubs in California and Massachusetts with emerging ecosystems elsewhere in the country.
The analysis finds that emerging-ecosystem companies generated higher median returns on invested capital at exit than their counterparts in established hubs. Startups in these emerging ecosystems also reached their first clinical trial milestones faster on average while requiring less private capital, and experienced less dilution, allowing founders to retain a greater share of ownership.
The report also highlights resilience in changing market conditions. Comparing the COVID-era period (2018–2021) with the post-COVID period (2022–2025), capital raised by companies in emerging ecosystems increased 23.3%, while established hubs experienced a 14.7% decline. The analysis further notes that companies outside traditional hubs accounted for nearly 70% of startups receiving SBIR/STTR grants, which the report presents as evidence of the importance of non-dilutive public funding for early-stage innovation.
The authors acknowledge that established hubs benefit from deep capital networks, specialized talent, and mature commercialization infrastructure. The report concludes that the future of U.S. biotech innovation depends on stronger connections across regional ecosystems rather than replicating the established hub model, and that improving access to follow-on capital, specialized infrastructure, and industry partnerships could help high-potential companies commercialize discoveries regardless of location. The full analysis is available from Portal Innovations' website.
The analysis finds that emerging-ecosystem companies generated higher median returns on invested capital at exit than their counterparts in established hubs. Startups in these emerging ecosystems also reached their first clinical trial milestones faster on average while requiring less private capital, and experienced less dilution, allowing founders to retain a greater share of ownership.
The report also highlights resilience in changing market conditions. Comparing the COVID-era period (2018–2021) with the post-COVID period (2022–2025), capital raised by companies in emerging ecosystems increased 23.3%, while established hubs experienced a 14.7% decline. The analysis further notes that companies outside traditional hubs accounted for nearly 70% of startups receiving SBIR/STTR grants, which the report presents as evidence of the importance of non-dilutive public funding for early-stage innovation.
The authors acknowledge that established hubs benefit from deep capital networks, specialized talent, and mature commercialization infrastructure. The report concludes that the future of U.S. biotech innovation depends on stronger connections across regional ecosystems rather than replicating the established hub model, and that improving access to follow-on capital, specialized infrastructure, and industry partnerships could help high-potential companies commercialize discoveries regardless of location. The full analysis is available from Portal Innovations' website.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.